Sandoz has announced the launch of the generic oncology medicine gefitinib indicated for adult patients with locally advanced or metastatic non-small cell lung cancer with activating mutations of EGFR-TK, which is recommended by ESMO as first-line treatment.
Swiss drugmaker Novartis has completed the acquisition of dry eye drug Xiidra (lifitegrast ophthalmic solution) 5% from Takeda for $3.4bn (£2.6bn) upfront in cash.
Bristol-Myers Squibb (BMS) is planning to divest Celgene’s psoriasis drug Otezla (apremilast), in a bid to expedite the process of merger with Celgene.
Dr. Reddy’s Laboratories announced the launch of Phytonadione Injectable Emulsion USP, 10 mg/ml Single-Dose Ampules, a therapeutic equivalent generic version of Vitamin K1 (Phytonadione) Injectable Emulsion USP, 10 mg/ml, approved by the U.S. Food and Drug Administration (USFDA).
Gamida Cell and Lonza announced that the companies have entered into a strategic manufacturing agreement.
Dr. Reddy’s Laboratories has entered into a definitive asset purchase agreement with Upsher-Smith Laboratories, pursuant to which Dr. Reddy’s would sell its US and select territory rights for ZEMBRACE SYMTOUCH (sumatriptan injection) 3 mg and TOSYMRA (sumatriptan nasal spray) 10 mg (formerly referred to as “DFN-02”), which are commercialized through its wholly owned subsidiary, Promius Pharma.
Debiopharm and Ipsen announced renewal of their Decapeptyl agreement, which extends and strengthens their strategic partnership through 2034 for the development, manufacturing and distribution of Decapeptyl across Europe and certain Asian and African markets.
UK-based Theramex has agreed to acquire exclusive licensing and supply rights from TherapeuticsMD to commercialise BIJUVA (estradiol and progesterone capsules) and IMVEXXY (estradiol vaginal inserts) outside of the US.
Neuraxpharm Group, a provider of treatments for central nervous system (CNS) disorders, is set to introduce its first probiotic in the European market.
Italy-based Chiesi Farmaceutici (Chiesi Group) has agreed to buy the licensing rights of Raxone (idebenone), an approved drug for Leber's hereditary optic neuropathy (LHON) in Europe, from Swiss pharma company Santhera Pharmaceuticals in a deal worth up to CHF105m (£82.5m).
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.